Shilpa Medicare Limited (SHILPAMED) gained +5% to near resistance at ₹635 on the NSE on 09 Jul 2026. The stock is testing resistance but has not cleared it, following a shift in trendline status from consolidation to approaching resistance. This move comes amid a corporate announcement regarding a credit rating update, which may have positively influenced investor sentiment. Shilpa Medicare, a mid-cap player in the specialty and generic drug manufacturing sector, has seen its stock price rise significantly over the past year, outperforming many of its peers.

Technical setup — trendlines & DMA

From a technical perspective, Shilpa Medicare’s current price is approaching the 6-month resistance trendline at ₹635, just 0.9% away. The stock has a solid 6-month support floor at ₹467.42, which is 25.76% below the current price. The 50-DMA at ₹512.8 is above the 200-DMA at ₹385.8, indicating a bullish trend. However, the stock is currently 16% above the 50-DMA, suggesting it is somewhat extended. In the 52-week range of ₹259.5 to ₹615.0, the current price is in the upper third, implying that a significant portion of the move is already priced in.

Fundamentals & business context

On the fundamental side, Shilpa Medicare’s PE of 47.7, coupled with a profit margin of 15.8% and a 5-year revenue CAGR of 13.8%, suggests that the market is pricing in growth expectations. However, the absence of profit CAGR over the same period indicates potential concerns about profitability. Institutional ownership stands at 10.6%, which is relatively low, suggesting that the ‘smart money’ is not heavily invested in this name. There was no specific NSE catalyst today beyond the credit rating announcement.

Algorithmic scorecard

The algorithmic scorecard reflects a technically strong but fundamentally weaker profile for Shilpa Medicare. The strongest signals include the bullish trend, with the 50-day average above the 200-day average, and the strong bullish sentiment over the last 30 days, where up days have seen 1.44x the volume of down days. These indicators suggest systematic accumulation and positive market sentiment. On the weaker side, the negligible dividend yield of 0.08% offers little income for investors, and the declining profit CAGR raises questions about the sustainability of growth. These factors should be carefully considered by investors.

Company outlook

Management’s forward guidance for FY27 is optimistic, with expectations for approval of the third U.S. NCE program, steady growth in the API business, and good growth possibilities in the formulation division. Key product launches, including Aflibercept and Nivolumab, are anticipated. Additionally, two NBE programs are expected to enter Phase I studies, and human studies for a second ADC biosimilar product are planned. The company also expects to start an India study for the recombinant human albumin program in the first half of FY27. Strategic plans include the commissioning of a new oncology block and a dedicated peptide large-scale manufacturing block, as well as the launch of NorUDCA globally. These initiatives underscore the company’s commitment to growth and innovation in the coming financial year.

Get all details on SHILPAMED — P&L, peers, shareholding and more on TradeAlone.